Hadasit Bio Holdings Ltd. (TASE:HDST; Bulletin Board: HADSD) has announced a $2 million investment from Chinese investors. The investors will receive one quarter of the company's shares in the placement, which reflected a company value of $6 million, after money.

Hadasit Bio is a holding company for companies founded on the basis of technology developed by the Hadassah Medical Center. The company currently has holdings in a number of companies, most of which are at various stages of clinical trials. Hadasit Bio's most prominent investments are in Cell Cure Neurosciences, which is in Phase I/IIa clinical trials for the use of stem cells in the treatment of age-related blindness; Enlivex, which is preparing for a Phase IIb or Phase III trial of its treatment for Graft Versus Host Disease (GVHD), a disease that attacks bone marrow implants, and which recently received an investment from a group led by Shai Novick; D-Pharm, which is developing drugs for treatment of stroke; and KAHR Medical, whose product treats autoimmune diseases and cancer, and which has obtained an investment from Sanofi. KAHR is also at the pre-clinical trials phase.

Hadasit Bio's market cap as of today was NIS 15 million ($4 million), meaning that the new investment is being made at a 50% premium on the market price (before today's substantial rise in the share price). In return for the investment, Hadasit Bio promised that it would do its best to make sure that the investor received the right to produce and market in China the products of Hadasit Bio's portfolio companies, and to establish a company development center in China, if an additional investment is made. Since all the companies in the group are legally independent, and some have additional investors, Hadasit does not have control over the grant of licenses on the portfolio companies' products, and can only make its best efforts, as the agreement specifies.
http://www.globes.co.il/en/article-chinese-investors-putting-2m-into-hadasit-1001048549

GOOD NEWS.

The investors seek to produce and market products of Hadasit's portfolio companies in China.

Hadasit Bio Holdings Ltd. (TASE:HDST; Bulletin Board: HADSD) has announced a $2 million investment from Chinese investors. The investors will receive one quarter of the company's shares in the placement, which reflected a company value of $6 million, after money.

Hadasit Bio is a holding company for companies founded on the basis of technology developed by the Hadassah Medical Center. The company currently has holdings in a number of companies, most of which are at various stages of clinical trials. Hadasit Bio's most prominent investments are in Cell Cure Neurosciences, which is in Phase I/IIa clinical trials for the use of stem cells in the treatment of age-related blindness; Enlivex, which is preparing for a Phase IIb or Phase III trial of its treatment for Graft Versus Host Disease (GVHD), a disease that attacks bone marrow implants, and which recently received an investment from a group led by Shai Novick; D-Pharm, which is developing drugs for treatment of stroke; and KAHR Medical, whose product treats autoimmune diseases and cancer, and which has obtained an investment from Sanofi. KAHR is also at the pre-clinical trials phase.

Hadasit Bio's market cap as of today was NIS 15 million ($4 million), meaning that the new investment is being made at a 50% premium on the market price (before today's substantial rise in the share price). In return for the investment, Hadasit Bio promised that it would do its best to make sure that the investor received the right to produce and market in China the products of Hadasit Bio's portfolio companies, and to establish a company development center in China, if an additional investment is made. Since all the companies in the group are legally independent, and some have additional investors, Hadasit does not have control over the grant of licenses on the portfolio companies' products, and can only make its best efforts, as the agreement specifies.
http://www.globes.co.il/en/article-chinese-investors-putting-2m-into-hadasit-1001048549

HADSY one for 5 reverse split:

http://otce.finra.org/DLSymbolNameChanges

A good setup. Beech cost $ 0.70. Are there any ideas? $ 0.50 - $ 0.70 is a good price to buy?

5 for 1 R/S

Excuse me. I'm an idiot. Instead of reading left to right, or even right to left, after a long day I have apparently been reading bottom to top.
In the previous post I referred to Hadasit as the company Phillip Frost was involved with. The relevant company is actually Protalix Biotherapeutics Inc. Hadasit is the previous company written about, and the newsletter had "Bio Holdings Ltd." in bold print directly above sentence fragment I quoted.
So after reading correctly, I don't know of any rumors about Frost and Hadasit.

Only rumors are from Stephen Petranek in Agora/Breakfthrough Technology Alert (April 2014).

"The second plus (for Hadasit) is the involvement of Phillip Frost in the company."

Anyone still around? Anyone heard any rumors of Philip Frost sniffing around?

So, one company with two tickers. Sounds like someone highjacked a corp.

Company Website:
http://www.hbl.co.il/default.asp

http://www.adrbnymellon.com/dr_profile.jsp?cusip=40409T109

Shares Outstanding 87,523,450 a/o Jul 20, 2011

Hadasit Bio-Holdings (TASE: HDST, OTC: HADSY) a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.

http://ih.advfn.com/p.php?pid=nmona&article=50851106&symbol=HADSY

Business Description Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) in order to allow public participation in the highly promising field of biotechnology. It serves as a precedent in biotech financing - for the first time, public investment is allowed to participate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").

Not quite sure how this is going to work, but Hadasit will be using several US and foriegn stocks to raise money for research.